Kane Biotech Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert B. Huizinga
- Full Time Employees
- 32
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 290-100 Innovation Drive Winnipeg MB Canada R3T 6G2
- IPO Date
- Mar 20, 2003
- Website
- kanebiotech.com
- Similar Companies
- Business
- Kane Biotech Inc. is a Canadian biotechnology firm dedicated to the investigation, advancement, and market introduction of solutions designed to inhibit and eradicate microbial biofilms globally. The company offers a range of innovative products, including the bluestem™ line for pet oral hygiene, utilizing its patented coactiv+™ technology. For human applications, Kane Biotech provides revyve™ Antimicrobial Wound Gel and Spray for various wound care needs, as well as the DispersinB® enzyme technology for wound and infection management. Additionally, it develops DermaKB™ scalp care products to address biofilm-related skin conditions. Expanding its portfolio, the company recently acquired FB Dermatology, adding LumiHeal® for chronic wounds and surgical scar reduction. Founded in 2001, Kane Biotech is headquartered in Winnipeg, Canada.
Company News
Kane Engages Independent Trading Group as Market Maker
Kane Biotech Signs Distribution Agreement with The Stevens Company
Kane to Showcase revyve® at Wounds Canada National Hybrid Conference
Kane Launches New Corporate Brand and Redesigned Website
Kane Biotech Announces $250,000 Insider Loan
Kane Biotech to Present Clinical Data and Showcase revyve® Product Line at SAWC Fall 2026
Kane Biotech Inc. (KNE:CA) Shareholder/Analyst Call Transcript
Kane Biotech to Host Commercial Update Webcast on September 16
Kane Biotech Expands Canadian Commercial Reach with Ontario Medical Supply Inc.
Kane Biotech Announces Second Quarter 2026 Financial Results
Kane Biotech Announces Engagement of DNA Advisors
Kane Biotech Announces Results of Annual and Special Meeting of Shareholders
Kane Biotech Inc. (KNE:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Kane Biotech Announces Grant of Stock Options
Kane Biotech Announces Grant of Stock Options
Kane Biotech Announces First Quarter 2026 Financial Results
Kane Biotech Announces the Oversubscription and Closing of Private Placement Offering
Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress
Kane Biotech Announces New Private Placement Offering
Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results